Jessica E Wijngaarden, Amina Ahbari, Johanna E E Pouw, Henri N J M Greuter, Idris Bahce, Gerben J C Zwezerijnen, Daniëlle J Vugts, Guus A M S van Dongen, Ronald Boellaard, C Willemien Menke-van der Houven van Oordt, Marc C Huisman
{"title":"如何从 89Zr-immuno-PET 扫描图像中获取血液浓度。","authors":"Jessica E Wijngaarden, Amina Ahbari, Johanna E E Pouw, Henri N J M Greuter, Idris Bahce, Gerben J C Zwezerijnen, Daniëlle J Vugts, Guus A M S van Dongen, Ronald Boellaard, C Willemien Menke-van der Houven van Oordt, Marc C Huisman","doi":"10.1186/s40658-024-00621-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PET scans using zirconium-89 labelled monoclonal antibodies (<sup>89</sup>Zr-mAbs), known as <sup>89</sup>Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of <sup>89</sup>Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive blood sampling. This study aims to identify the best delineation strategy to obtain the image-derived blood concentration (IDBC) from <sup>89</sup>Zr-immuno-PET scans.</p><p><strong>Methods: </strong>PET imaging and blood sampling of two <sup>89</sup>Zr-mAbs were included, <sup>89</sup>Zr-cetuximab and <sup>89</sup>Zr-durvalumab. For seven patients receiving <sup>89</sup>Zr-cetuximab, PET scans on 1-2 h, 2 and 6 days post-injection (p.i.) were analysed. Five patients received three injections of <sup>89</sup>Zr-durvalumab. The scanning protocol for the first two injections consisted of PET scanning on 2, 5 and 7 days p.i. and for the third injection only on 7 days p.i. Blood samples were drawn with every PET scan and the sample-derived blood concentration (SDBC) was used as gold standard for the IDBC. According to an in-house developed standard operating procedure, the aortic arch, ascending aorta, descending aorta and left ventricle were delineated. Bland-Altman analyses were performed to assess the bias (mean difference) and variability (1.96 times the standard deviation of the differences) between IDBC and SDBC.</p><p><strong>Results: </strong>Overall, the activity concentration obtained from the IDBC was lower than from the SDBC. When comparing IDBC with SDBC, variability was smallest for the ascending aorta (20.3% and 17.0% for <sup>89</sup>Zr-cetuximab and <sup>89</sup>Zr-durvalumab, respectively). Variability for the other regions ranged between 17.9 and 30.8%. Bias for the ascending aorta was - 10.9% and - 11.4% for <sup>89</sup>Zr-cetuximab and <sup>89</sup>Zr-durvalumab, respectively.</p><p><strong>Conclusions: </strong>Image-derived blood concentrations should be obtained from delineating the ascending aorta in <sup>89</sup>Zr-immuno-PET scans, as this results in the lowest variability with respect to sample-derived blood concentrations.</p>","PeriodicalId":11559,"journal":{"name":"EJNMMI Physics","volume":"11 1","pages":"16"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847076/pdf/","citationCount":"0","resultStr":"{\"title\":\"How to obtain the image-derived blood concentration from <sup>89</sup>Zr-immuno-PET scans.\",\"authors\":\"Jessica E Wijngaarden, Amina Ahbari, Johanna E E Pouw, Henri N J M Greuter, Idris Bahce, Gerben J C Zwezerijnen, Daniëlle J Vugts, Guus A M S van Dongen, Ronald Boellaard, C Willemien Menke-van der Houven van Oordt, Marc C Huisman\",\"doi\":\"10.1186/s40658-024-00621-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>PET scans using zirconium-89 labelled monoclonal antibodies (<sup>89</sup>Zr-mAbs), known as <sup>89</sup>Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of <sup>89</sup>Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive blood sampling. This study aims to identify the best delineation strategy to obtain the image-derived blood concentration (IDBC) from <sup>89</sup>Zr-immuno-PET scans.</p><p><strong>Methods: </strong>PET imaging and blood sampling of two <sup>89</sup>Zr-mAbs were included, <sup>89</sup>Zr-cetuximab and <sup>89</sup>Zr-durvalumab. For seven patients receiving <sup>89</sup>Zr-cetuximab, PET scans on 1-2 h, 2 and 6 days post-injection (p.i.) were analysed. Five patients received three injections of <sup>89</sup>Zr-durvalumab. The scanning protocol for the first two injections consisted of PET scanning on 2, 5 and 7 days p.i. and for the third injection only on 7 days p.i. Blood samples were drawn with every PET scan and the sample-derived blood concentration (SDBC) was used as gold standard for the IDBC. According to an in-house developed standard operating procedure, the aortic arch, ascending aorta, descending aorta and left ventricle were delineated. Bland-Altman analyses were performed to assess the bias (mean difference) and variability (1.96 times the standard deviation of the differences) between IDBC and SDBC.</p><p><strong>Results: </strong>Overall, the activity concentration obtained from the IDBC was lower than from the SDBC. When comparing IDBC with SDBC, variability was smallest for the ascending aorta (20.3% and 17.0% for <sup>89</sup>Zr-cetuximab and <sup>89</sup>Zr-durvalumab, respectively). Variability for the other regions ranged between 17.9 and 30.8%. Bias for the ascending aorta was - 10.9% and - 11.4% for <sup>89</sup>Zr-cetuximab and <sup>89</sup>Zr-durvalumab, respectively.</p><p><strong>Conclusions: </strong>Image-derived blood concentrations should be obtained from delineating the ascending aorta in <sup>89</sup>Zr-immuno-PET scans, as this results in the lowest variability with respect to sample-derived blood concentrations.</p>\",\"PeriodicalId\":11559,\"journal\":{\"name\":\"EJNMMI Physics\",\"volume\":\"11 1\",\"pages\":\"16\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847076/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40658-024-00621-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40658-024-00621-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans.
Background: PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive blood sampling. This study aims to identify the best delineation strategy to obtain the image-derived blood concentration (IDBC) from 89Zr-immuno-PET scans.
Methods: PET imaging and blood sampling of two 89Zr-mAbs were included, 89Zr-cetuximab and 89Zr-durvalumab. For seven patients receiving 89Zr-cetuximab, PET scans on 1-2 h, 2 and 6 days post-injection (p.i.) were analysed. Five patients received three injections of 89Zr-durvalumab. The scanning protocol for the first two injections consisted of PET scanning on 2, 5 and 7 days p.i. and for the third injection only on 7 days p.i. Blood samples were drawn with every PET scan and the sample-derived blood concentration (SDBC) was used as gold standard for the IDBC. According to an in-house developed standard operating procedure, the aortic arch, ascending aorta, descending aorta and left ventricle were delineated. Bland-Altman analyses were performed to assess the bias (mean difference) and variability (1.96 times the standard deviation of the differences) between IDBC and SDBC.
Results: Overall, the activity concentration obtained from the IDBC was lower than from the SDBC. When comparing IDBC with SDBC, variability was smallest for the ascending aorta (20.3% and 17.0% for 89Zr-cetuximab and 89Zr-durvalumab, respectively). Variability for the other regions ranged between 17.9 and 30.8%. Bias for the ascending aorta was - 10.9% and - 11.4% for 89Zr-cetuximab and 89Zr-durvalumab, respectively.
Conclusions: Image-derived blood concentrations should be obtained from delineating the ascending aorta in 89Zr-immuno-PET scans, as this results in the lowest variability with respect to sample-derived blood concentrations.
期刊介绍：
EJNMMI Physics is an international platform for scientists, users and adopters of nuclear medicine with a particular interest in physics matters. As a companion journal to the European Journal of Nuclear Medicine and Molecular Imaging, this journal has a multi-disciplinary approach and welcomes original materials and studies with a focus on applied physics and mathematics as well as imaging systems engineering and prototyping in nuclear medicine. This includes physics-driven approaches or algorithms supported by physics that foster early clinical adoption of nuclear medicine imaging and therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
